Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease.
Adult
Aged
Aged, 80 and over
Autoimmune Diseases
/ complications
Bisphosphonate-Associated Osteonecrosis of the Jaw
/ epidemiology
Bone Density Conservation Agents
/ adverse effects
Diphosphonates
/ adverse effects
Female
Humans
Incidence
Male
Middle Aged
Osteoporotic Fractures
/ complications
Retrospective Studies
Risk Factors
Tooth Extraction
/ adverse effects
Withholding Treatment
Young Adult
Antiresorptive agents-related osteonecrosis of the jaw
Autoimmune disease
Osteoporosis
Rheumatoid arthritis
Journal
Journal of bone and mineral metabolism
ISSN: 1435-5604
Titre abrégé: J Bone Miner Metab
Pays: Japan
ID NLM: 9436705
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
15
06
2019
accepted:
02
02
2020
pubmed:
23
2
2020
medline:
15
8
2020
entrez:
21
2
2020
Statut:
ppublish
Résumé
Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is a rare but serious complication in patients receiving antiresorprtive agents (AR). However, the incidence of ARONJ after tooth extraction in patients with autoimmune disease (AID) remains unclear. The present study aimed to clarify the high-risk population of ARONJ in patients with AID. The study population comprised 232 patients treated with AR, AID or non-AID, who had undergone dental extraction from January 2011 to September 2017. The incidence and risk factors of ARONJ were analysed retrospectively. Additionally, the relationship between ARONJ and osteoporotic fracture (OF) and AR discontinuation during dental procedures was investigated. Of 232 patients, 10 developed ARONJ within 1 year of dental extraction. The incidence of ARONJ in patients with AID was higher than that in non-AID patients (2.0/100 person-year vs 0.5/100 person-year; p = 0.03). Among the AID patients, RA patients had strikingly high incidence of ARONJ (3.6/100 person-year). The incidence of neither ARONJ nor OF significantly differed between patients who continued and discontinued AR in the perioperative period. Patients with AID who undergo dental extraction are at high risk of ARONJ. Discontinuation of AR would not significantly contribute to reduce the incidence of ARONJ in those patients.
Identifiants
pubmed: 32076874
doi: 10.1007/s00774-020-01089-y
pii: 10.1007/s00774-020-01089-y
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
581-588Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Tanaka S, Tanaka Y, Ishiguro N, Yamanaka H, Takeuchi T (2018) RANKL: a therapeutic target for bone destruction in rheumatoid arthritis. Mod Rheumatol 28:9–16. https://doi.org/10.1080/14397595.2017.1369491
doi: 10.1080/14397595.2017.1369491
pubmed: 28880683
Beumer J 3rd, Silverman S Jr, Benak SB Jr (1972) Hard and soft tissue necroses following radiation therapy for oral cancer. J Prosthet Dent 27:640–644
doi: 10.1016/0022-3913(72)90311-3
Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H, American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive A (2011) Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243–1251
doi: 10.14219/jada.archive.2011.0108
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F, American Association of O, Maxillofacial S (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72:1938–1956. https://doi.org/10.1016/j.joms.2014.04.031
doi: 10.1016/j.joms.2014.04.031
Japanese Allied Committee on Osteonecrosis of the J, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S (2017) Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6–19. https://doi.org/10.1007/s00774-016-0810-7
doi: 10.1007/s00774-016-0810-7
Holzinger D, Seemann R, Matoni N, Ewers R, Millesi W, Wutzl A (2014) Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 72:e1–e8. https://doi.org/10.1016/j.joms.2014.04.037
doi: 10.1016/j.joms.2014.04.037
Matsuo Y, Ogawa T, Yamamoto M, Shibamoto A, Saenz JRV, Yokoyama M, Kanda Y, Toyohara J, Sasaki K (2017) Evaluation of peri-implant bone metabolism under immediate loading using high-resolution Na(18)F-PET. Clin Oral Investig 21:2029–2037. https://doi.org/10.1007/s00784-016-1992-z
doi: 10.1007/s00784-016-1992-z
pubmed: 27838843
Taguchi A, Shiraki M, Tsukiyama M, Miyazaki T, Soen S, Ohta H, Nakamura T, Orimo H (2015) Impact of osteonecrosis of the jaw on osteoporosis treatment in Japan: results of a questionnaire-based survey by the Adequate Treatment of Osteoporosis (A-TOP) Research Group. Calcif Tissue Int 97:542–550. https://doi.org/10.1007/s00223-015-0045-y
doi: 10.1007/s00223-015-0045-y
pubmed: 26210799
Taguchi A, Shiraki M, Sugimoto T, Ohta H, Soen S, Japan Osteoporosis S (2016) Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw. Curr Med Res Opin 32:1261–1268. https://doi.org/10.1185/03007995.2016.1170005
doi: 10.1185/03007995.2016.1170005
pubmed: 27007294
Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19:1613–1620. https://doi.org/10.1007/s00198-008-0604-4
doi: 10.1007/s00198-008-0604-4
pubmed: 18483689
pmcid: 2574626
Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT et al (2010) The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: phase 2 methodological report. Arthritis Rheum 62:2582–2591. https://doi.org/10.1002/art.27580
doi: 10.1002/art.27580
pubmed: 20872596
pmcid: 3077961
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https://doi.org/10.1002/1529-0131(199709)40:9%3c1725:AID-ART29%3e3.0.CO;2-Y
doi: 10.1002/1529-0131(199709)40:9%3c1725::AID-ART29%3e3.0.CO;2-Y
Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K (2004) Revised Japanese criteria for Sjogren’s syndrome (1999): availability and validity. Mod Rheumatol 14:425–434. https://doi.org/10.3109/s10165-004-0338-x
doi: 10.3109/s10165-004-0338-x
pubmed: 24387718
Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227. https://doi.org/10.1136/ard.2006.054593
doi: 10.1136/ard.2006.054593
Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129–1134
doi: 10.1002/art.1780330811
Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, Masi AT, Mcshane DJ, Mills JA, Wallace SL, Zvaifler NJ (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129–1134
pubmed: 1975175
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347. https://doi.org/10.1056/NEJM197502132920706
doi: 10.1056/NEJM197502132920706
pubmed: 1090839
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737–2747. https://doi.org/10.1002/art.38098
doi: 10.1002/art.38098
pubmed: 24122180
pmcid: 3930146
Davatchi F (2012) Diagnosis/classification criteria for Behcet’s disease. Patholog Res Int 2012:607921. https://doi.org/10.1155/2012/607921
doi: 10.1155/2012/607921
pubmed: 21961081
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, Group CS (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673. https://doi.org/10.1002/art.21972
doi: 10.1002/art.21972
Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M et al (2012) 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 64:943–954. https://doi.org/10.1002/art.34356
doi: 10.1002/art.34356
pubmed: 22389040
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, den Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x
doi: 10.1111/j.1538-7836.2006.01753.x
McAdam LP, O'Hanlan MA, Bluestone R, Pearson CM (1976) Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 55:193–215
doi: 10.1097/00005792-197605000-00001
Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T, Japanese Society for B, Mineral R, Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary O (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247–257. https://doi.org/10.1007/s00774-013-0447-8
doi: 10.1007/s00774-013-0447-8
pubmed: 23553500
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23. https://doi.org/10.1002/jbmr.2405
doi: 10.1002/jbmr.2405
pubmed: 25414052
Uyanne J, Calhoun CC, Le AD (2014) Antiresorptive drug-related osteonecrosis of the jaw. Dent Clin North Am 58:369–384. https://doi.org/10.1016/j.cden.2013.12.006
doi: 10.1016/j.cden.2013.12.006
pubmed: 24655528
Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, Kondou E, Takeda D, Kojima Y, Sato S, Yanamoto S, Komatsubara H, Umeda M, Kirita T, Kurita H, Shibuya Y, Komori T, Japanese Study Group of Cooperative Dentistry with M (2017) A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int 28:2465–2473. https://doi.org/10.1007/s00198-017-4063-7
doi: 10.1007/s00198-017-4063-7
pubmed: 28451732
Conte Neto N, Bastos AS, Chierici-Marcantonio RA, Marcantonio E Jr (2011) Is rheumatoid arthritis a risk factor for oral bisphosphonate-induced osteonecrosis of the jaws? Med Hypotheses 77:905–911. https://doi.org/10.1016/j.mehy.2011.08.008
doi: 10.1016/j.mehy.2011.08.008
pubmed: 21885199
Kindstedt E, Johansson L, Palmqvist P, Koskinen Holm C, Kokkonen H, Johansson I, Rantapaa Dahlqvist S, Lundberg P (2018) Association between Marginal Jawbone Loss and Onset of Rheumatoid arthritis and relationship to plasma levels of RANKL. Arthritis Rheumatol 70:508–515. https://doi.org/10.1002/art.40394
doi: 10.1002/art.40394
Abtahi J, Agholme F, Sandberg O, Aspenberg P (2013) Effect of local vs. systemic bisphosphonate delivery on dental implant fixation in a model of osteonecrosis of the jaw. J Dent Res 92:279–283. https://doi.org/10.1177/0022034512472335
doi: 10.1177/0022034512472335
pubmed: 23264610
Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC (2009) Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45:164–172. https://doi.org/10.1016/j.oraloncology.2008.04.013
doi: 10.1016/j.oraloncology.2008.04.013
pubmed: 18715819
Furuya T, Maeda S, Momohara S, Taniguchi A, Yamanaka H (2017) Dental treatments, tooth extractions, and osteonecrosis of the jaw in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study. J Bone Miner Metab 35:344–350. https://doi.org/10.1007/s00774-016-0763-x
doi: 10.1007/s00774-016-0763-x
pubmed: 27372662
Allen MR (2015) Medication-related osteonecrosis of the jaw: basic and translational science updates. Oral Maxillofac Surg Clin North Am 27:497–508. https://doi.org/10.1016/j.coms.2015.06.002
doi: 10.1016/j.coms.2015.06.002
pubmed: 26277349
Aghaloo TL, Cheong S, Bezouglaia O, Kostenuik P, Atti E, Dry SM, Pirih FQ, Tetradis S (2014) RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease. J Bone Miner Res 29:843–854. https://doi.org/10.1002/jbmr.2097
doi: 10.1002/jbmr.2097
pubmed: 24115073
pmcid: 4476544
de Molon RS, Shimamoto H, Bezouglaia O, Pirih FQ, Dry SM, Kostenuik P, Boyce RW, Dwyer D, Aghaloo TL, Tetradis S (2015) OPG-Fc but Not Zoledronic Acid discontinuation reverses Osteonecrosis of the Jaws (ONJ) in mice. J Bone Miner Res 30:1627–1640. https://doi.org/10.1002/jbmr.2490
doi: 10.1002/jbmr.2490
pubmed: 25727550
pmcid: 4995600
Hinson AM, Smith CW, Siegel ER, Stack BC Jr (2014) Is bisphosphonate-related osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary. Int J Dent 2014:452737. https://doi.org/10.1155/2014/452737
doi: 10.1155/2014/452737
pubmed: 25089126
pmcid: 4095654